| scholarly article | Q13442814 |
| P2093 | author name string | Andrew G MacLean | |
| Tiffany A Peterson | |||
| P2860 | cites work | Mass Cytometric Analysis of HIV Entry, Replication, and Remodeling in Tissue CD4+ T Cells | Q38659872 |
| HIV-1 Eradication: Early Trials (and Tribulations). | Q38675631 | ||
| Translation initiation of the HIV-1 mRNA. | Q38700670 | ||
| A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape. | Q38759997 | ||
| MiRNA-Mediated Macrophage Polarization and its Potential Role in the Regulation of Inflammatory Response | Q38765627 | ||
| Conserved Interaction of Lentiviral Vif Molecules with HIV-1 Gag and Differential Effects of Species-Specific Vif on Virus Production. | Q38765818 | ||
| Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex | Q38818673 | ||
| Antiviral Efficacy of a Respiratory Syncytial Virus (RSV) Fusion Inhibitor in a Bovine Model of RSV Infection | Q38866056 | ||
| Infection of the choroid plexus by feline immunodeficiency virus | Q38919455 | ||
| Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cells | Q38924992 | ||
| Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications | Q38936786 | ||
| Lymphocyte migration through the blood-brain barrier (BBB) in feline immunodeficiency virus infection is significantly influenced by the pre-existence of virus and tumour necrosis factor (TNF)-alpha within the central nervous system (CNS): studies u | Q39006283 | ||
| Three viruses of the bovine respiratory disease complex apply different strategies to initiate infection | Q39022931 | ||
| CCR5 Disruption in Induced Pluripotent Stem Cells Using CRISPR/Cas9 Provides Selective Resistance of Immune Cells to CCR5-tropic HIV-1 Virus | Q39119223 | ||
| Novel AIDS therapies based on gene editing | Q39140209 | ||
| Caveolin-1-mediated endocytic pathway is involved in classical swine fever virus Shimen infection of porcine alveolar macrophages | Q39258844 | ||
| Reactivation of latent HIV-1 by inhibition of BRD4. | Q39264882 | ||
| A Critical Review of the Evidence Concerning the HIV Latency Reversing Effect of Disulfiram, the Possible Explanations for Its Inability to Reduce the Size of the Latent Reservoir In Vivo, and the Caveats Associated with Its Use in Practice | Q39279515 | ||
| Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART. | Q39378079 | ||
| CCR5 monoclonal antibodies for HIV-1 therapy | Q22242739 | ||
| HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes | Q22252313 | ||
| A Literature Review of Zika Virus | Q24261125 | ||
| Zika Virus Infects Human Placental Macrophages | Q24278525 | ||
| Identification of host proteins required for HIV infection through a functional genomic screen | Q24306298 | ||
| Dengue virus requires the CC-chemokine receptor CCR5 for replication and infection development | Q26700116 | ||
| Epigenetic control of HIV-1 post integration latency: implications for therapy | Q26781191 | ||
| West Nile Virus: biology, transmission, and human infection | Q26865618 | ||
| Pharmacological inhibition of feline immunodeficiency virus (FIV) | Q26995310 | ||
| Inhibition of human immunodeficiency virus type-1 through autophagy | Q27005938 | ||
| HIV-1 reverse transcription | Q27023387 | ||
| The soluble form of the EIAV receptor encoded by an alternative splicing variant inhibits EIAV infection of target cells | Q27302868 | ||
| Adipose Tissue Is a Neglected Viral Reservoir and an Inflammatory Site during Chronic HIV and SIV Infection | Q27317216 | ||
| CD4 depletion in SIV-infected macaques results in macrophage and microglia infection with rapid turnover of infected cells | Q27322949 | ||
| Heparan Sulfate Proteoglycans Mediate Attachment and Entry of Human T-Cell Leukemia Virus Type 1 Virions into CD4+ T Cells | Q27472216 | ||
| ZIKA virus reveals broad tissue and cell tropism during the first trimester of pregnancy | Q27928019 | ||
| Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies | Q28066335 | ||
| Targeting the Brain Reservoirs: Toward an HIV Cure | Q28075694 | ||
| Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate Immune Responses | Q28222232 | ||
| Bovine viral diarrhea virus type 2 in vivo infection modulates TLR4 responsiveness in differentiated myeloid cells which is associated with decreased MyD88 expression | Q28262916 | ||
| Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans | Q28345408 | ||
| Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis | Q28484930 | ||
| Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation | Q28546901 | ||
| An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression | Q28546918 | ||
| Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene | Q29614892 | ||
| Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection | Q29619510 | ||
| Macrophage biology in development, homeostasis and disease | Q29620350 | ||
| Monocytes-macrophages are a potential target in human infection with West Nile virus through blood transfusion | Q33238490 | ||
| Equine Infectious Anemia Virus (EIAV): what has HIV's country cousin got to tell us? | Q33361581 | ||
| A non-canonical binding interface in the crystal structure of HIV-1 gp120 core in complex with CD4 | Q33587774 | ||
| Antibodies to watch in 2018. | Q50120289 | ||
| Human dendritic cell subsets: an update. | Q50125373 | ||
| Induction of a Senescence-Like Phenotype in Cultured Human Fetal Microglia During HIV-1 Infection. | Q50133032 | ||
| DC-SIGN-ICAM-2 interaction mediates dendritic cell trafficking. | Q50335867 | ||
| HIV and the Macrophage: From Cell Reservoirs to Drug Delivery to Viral Eradication. | Q51760002 | ||
| The latest evidence for possible HIV-1 curative strategies. | Q52430553 | ||
| Developing and evaluating inhibitors against the RNase H active site of HIV-1 RT. | Q52593232 | ||
| Adult antiretroviral therapy guidelines 2017. | Q52641448 | ||
| A CCR5 antagonist-based HIV entry inhibitor exhibited potent spermicidal activity: Potential application for contraception and prevention of HIV sexual transmission. | Q52678517 | ||
| Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication. | Q52687754 | ||
| Maraviroc is associated with latent HIV-1 reactivation through NF-κB activation in resting CD4+ T cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy. | Q52695029 | ||
| CRISPR/Cas9 inhibits multiple steps of HIV-1 infection. | Q52719897 | ||
| Novel Latency Reversal Agents for HIV-1 Cure. | Q52816327 | ||
| Multilayered and versatile inhibition of cellular antiviral factors by HIV and SIV accessory proteins. | Q54258406 | ||
| Lessons Learned in Developing a Commercial FIV Vaccine: The Immunity Required for an Effective HIV-1 Vaccine. | Q54984932 | ||
| Nanoformulated Antiretroviral Therapy Attenuates Brain Metabolic Oxidative Stress | Q59355519 | ||
| On the way to find a cure: Purging latent HIV-1 reservoirs | Q39421878 | ||
| A Consensus View of ESCRT-Mediated Human Immunodeficiency Virus Type 1 Abscission. | Q39439244 | ||
| Critical Role for Monocytes/Macrophages in Rapid Progression to AIDS in Pediatric Simian Immunodeficiency Virus-Infected Rhesus Macaques. | Q39496551 | ||
| Respiratory syncytial virus (RSV) fusion protein subunit F2, not attachment protein G, determines the specificity of RSV infection | Q39742113 | ||
| On the Whereabouts of HIV-1 Cellular Entry and Its Fusion Ports | Q40044914 | ||
| The integration of a macrophage-adapted live vaccine strain of equine infectious anaemia virus (EIAV) in the horse genome | Q40051498 | ||
| Pathogenesis and Molecular Mechanisms of Zika Virus | Q40054986 | ||
| AR-12 suppresses dengue virus replication by down-regulation of PI3K/AKT and GRP78. | Q40067572 | ||
| One-domain CD4 Fused to Human Anti-CD16 Antibody Domain Mediates Effective Killing of HIV-1-Infected Cells. | Q40074629 | ||
| The poly-proline tail of SIVmac Vpx provides gain of function for resistance to a cryptic proteasome-dependent degradation pathway | Q40084910 | ||
| Potent In Vivo NK Cell-mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-bispecific and Hexavalent Broadly Neutralizing Fusion Protein. | Q40088787 | ||
| Central and peripheral reservoirs of feline immunodeficiency virus in cats: a review | Q40106145 | ||
| Current status of the Pharmacokinetics and Pharmacodynamics of HIV-1 Entry Inhibitors and HIV Therapy | Q40110543 | ||
| Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition | Q40141950 | ||
| A Novel Bromodomain Inhibitor Reverses HIV-1 Latency through Specific Binding with BRD4 to Promote Tat and P-TEFb Association. | Q40150438 | ||
| Patterns of gene expression in swine macrophages infected with classical swine fever virus detected by microarray. | Q40363429 | ||
| Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques | Q40424592 | ||
| Classical swine fever virus inhibits nitric oxide production in infected macrophages | Q40436552 | ||
| Insulin Treatment Prevents Neuroinflammation and Neuronal Injury with Restored Neurobehavioral Function in Models of HIV/AIDS Neurodegeneration. | Q40508985 | ||
| Long-term HIV-1 infection induces an antiviral state in primary macrophages | Q40580939 | ||
| Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study | Q40668686 | ||
| Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells | Q41265657 | ||
| Bovine immunodeficiency virus: a lentiviral infection | Q41812731 | ||
| Secondary structure of the HIV reverse transcription initiation complex by NMR. | Q41814101 | ||
| Suppression of immunodeficiency virus-associated neural damage by the p75 neurotrophin receptor ligand, LM11A-31, in an in vitro feline model | Q41877371 | ||
| Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry | Q42126903 | ||
| Bovine viral diarrhea virus infection affects the expression of proteins related to professional antigen presentation in bovine monocytes | Q42982353 | ||
| Designing broad-spectrum anti-HIV-1 gRNAs to target patient-derived variants. | Q43212335 | ||
| Feline Immunodeficiency Virus Neuropathogenesis: A Model for HIV-Induced CNS Inflammation and Neurodegeneration | Q43378566 | ||
| Choroid plexus macrophages proliferate and release toxic factors in response to feline immunodeficiency virus | Q44020129 | ||
| Astrocytes and microglia differentially regulate trafficking of lymphocyte subsets across brain endothelial cells | Q44863299 | ||
| Detection of proviral DNA of bovine immunodeficiency virus in bovine tissues by polymerase chain reaction (PCR) and PCR in situ hybridization | Q45760216 | ||
| Neurologic disease in feline immunodeficiency virus infection: disease mechanisms and therapeutic interventions for NeuroAIDS. | Q46238563 | ||
| Role of Monocyte/Macrophages during HIV/SIV Infection in Adult and Pediatric Acquired Immune Deficiency Syndrome | Q47100536 | ||
| Myeloid Cell Interaction with HIV: A Complex Relationship. | Q47141408 | ||
| Modern biotechnology-based therapeutic approaches against HIV infection | Q47179848 | ||
| Cell and Gene Therapy for HIV Cure | Q47236016 | ||
| Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir | Q47261168 | ||
| Type I Interferon Responses by HIV-1 Infection: Association with Disease Progression and Control | Q47548056 | ||
| Preventing HIV transmission through blockade of CCR5: rationale, progress and perspectives | Q47548412 | ||
| CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose | Q47549474 | ||
| Single-molecule techniques to quantify and genetically characterise persistent HIV. | Q47556373 | ||
| Hybrid magneto-plasmonic liposomes for multimodal image-guided and brain-targeted HIV treatment. | Q47568994 | ||
| Molecular Control of HIV and SIV Latency | Q47600043 | ||
| Beyond the replication-competent HIV reservoir: transcription and translation-competent reservoirs. | Q48113493 | ||
| Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. | Q48425484 | ||
| The role of latency reversal agents in the cure of hiv: A review of current data. | Q48502845 | ||
| Barrier-tissue macrophages: functional adaptation to environmental challenges. | Q49048144 | ||
| Niche signals and transcription factors involved in tissue-resident macrophage development. | Q49793888 | ||
| Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents. | Q49925023 | ||
| Recent updates for designing CCR5 antagonists as anti-retroviral agents. | Q50096558 | ||
| Exceptional Potency and Structural Basis of a T1249-Derived Lipopeptide Fusion Inhibitor against HIV-1, HIV-2, and Simian Immunodeficiency Virus. | Q50099962 | ||
| Macrophage plasticity, polarization and function in health and disease. | Q50107325 | ||
| Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo | Q33652566 | ||
| Modulation of innate immune signaling by the secreted form of the West Nile virus NS1 glycoprotein | Q33821633 | ||
| Serum Metabolomics Investigation of Humanized Mouse Model of Dengue Virus Infection | Q33843566 | ||
| Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline | Q33987146 | ||
| RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. | Q34025414 | ||
| Transcriptional and posttranscriptional regulation of HIV-1 gene expression | Q34030804 | ||
| Receptor-mediated entry by equine infectious anemia virus utilizes a pH-dependent endocytic pathway | Q34142939 | ||
| Marine natural products: bryostatins in preclinical and clinical studies | Q34370858 | ||
| Genetic acceleration of AIDS progression by a promoter variant of CCR5. | Q34481958 | ||
| Equine viperin restricts equine infectious anemia virus replication by inhibiting the production and/or release of viral Gag, Env, and receptor via distortion of the endoplasmic reticulum | Q34593906 | ||
| Retroviral integrase proteins and HIV-1 DNA integration | Q34643561 | ||
| Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus | Q34655645 | ||
| Macrophages: development and tissue specialization | Q34669239 | ||
| Macrophage infection via selective capture of HIV-1-infected CD4+ T cells | Q34742795 | ||
| Infection of equine monocyte-derived macrophages with an attenuated equine infectious anemia virus (EIAV) strain induces a strong resistance to the infection by a virulent EIAV strain | Q34812619 | ||
| A novel real-time CTL assay to measure designer T-cell function against HIV Env(+) cells | Q35052987 | ||
| Autophagy induction by histone deacetylase inhibitors inhibits HIV type 1. | Q35103991 | ||
| Distinct requirements for HIV-cell fusion and HIV-mediated cell-cell fusion. | Q35173023 | ||
| The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA | Q35177829 | ||
| HIV-1 target cells in the CNS. | Q35196509 | ||
| Reverse Transcriptase and Cellular Factors: Regulators of HIV-1 Reverse Transcription. | Q35260021 | ||
| West Nile virus: immunity and pathogenesis | Q35261421 | ||
| Virus receptors: implications for pathogenesis and the design of antiviral agents. | Q35366667 | ||
| HIV Excision Utilizing CRISPR/Cas9 Technology: Attacking the Proviral Quasispecies in Reservoirs to Achieve a Cure | Q35447267 | ||
| Viral determinants of HIV-1 macrophage tropism | Q35593158 | ||
| Genome editing strategies: potential tools for eradicating HIV-1/AIDS. | Q35612053 | ||
| Making sense of how HIV kills infected CD4 T cells: implications for HIV cure | Q35673909 | ||
| Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. | Q35720063 | ||
| HIV Blocks Interferon Induction in Human Dendritic Cells and Macrophages by Dysregulation of TBK1 | Q35745385 | ||
| Protein Kinase C: One Pathway towards the Eradication of Latent HIV-1 Reservoirs | Q35830264 | ||
| Macrophage Polarization in Virus-Host Interactions | Q35882034 | ||
| HIV-1 induces telomerase activity in monocyte-derived macrophages, possibly safeguarding one of its reservoirs. | Q36276462 | ||
| Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein | Q36332978 | ||
| Mapping of Receptor Binding Interactions with the FIV surface Glycoprotein (SU); Implications Regarding Immune surveillance and cellular Targets of Infection | Q36470890 | ||
| The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation | Q36668708 | ||
| CRISPR-mediated Activation of Latent HIV-1 Expression | Q36675297 | ||
| Macrophages sustain HIV replication in vivo independently of T cells | Q36737917 | ||
| Bovine HEXIM1 inhibits bovine immunodeficiency virus replication through regulating BTat-mediated transactivation | Q36777646 | ||
| Circularization of human immunodeficiency virus type 1 DNA in vitro | Q36828935 | ||
| HIV-1 Vpr: mechanisms of G2 arrest and apoptosis | Q37029922 | ||
| Colony-Stimulating Factor 1 Receptor Antagonists Sensitize Human Immunodeficiency Virus Type 1-Infected Macrophages to TRAIL-Mediated Killing | Q37073330 | ||
| Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment. | Q37102101 | ||
| The HIV-1 protein Vpr targets the endoribonuclease Dicer for proteasomal degradation to boost macrophage infection | Q37126033 | ||
| Negative Feedback Regulation of HIV-1 by Gene Editing Strategy | Q37177251 | ||
| Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection | Q37273158 | ||
| Small ruminant macrophage polarization may play a pivotal role on lentiviral infection. | Q37363412 | ||
| Resolution and prevention of feline immunodeficiency virus-induced neurological deficits by treatment with the protease inhibitor TL-3. | Q37423412 | ||
| Antibodies to watch in 2017 | Q37631319 | ||
| Distribution and fate of HIV-1 unintegrated DNA species: a comprehensive update | Q37649116 | ||
| New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. | Q37695001 | ||
| Macrophages as susceptible targets for HIV infection, persistent viral reservoirs in tissue, and key immunoregulatory cells that control levels of virus replication and extent of disease | Q37974635 | ||
| Small ruminant lentiviruses: immunopathogenesis of visna-maedi and caprine arthritis and encephalitis virus | Q37975072 | ||
| Respiratory syncytial virus persistence in macrophages alters the profile of cellular gene expression | Q38076133 | ||
| Virus interactions with endocytic pathways in macrophages and dendritic cells | Q38119660 | ||
| HIV-1 latency in monocytes/macrophages | Q38206643 | ||
| Monocytes and macrophages: developmental pathways and tissue homeostasis | Q38214042 | ||
| HIV-1 translation and its regulation by cellular factors PKR and PACT. | Q38234190 | ||
| Cell-to-cell transfer of HIV infection: implications for HIV viral persistence | Q38242047 | ||
| Porcine circovirus type 2 (PCV2): pathogenesis and interaction with the immune system | Q38267078 | ||
| Biology and pathogenesis of lentiviruses | Q38275020 | ||
| Monoclonal antibodies to host cellular receptors for the treatment and prevention of HIV-1 infection | Q38362894 | ||
| Proteomic alteration of equine monocyte-derived macrophages infected with equine infectious anemia virus | Q38466790 | ||
| BVDV vaccination in North America: risks versus benefits | Q38518785 | ||
| Origin of microglia: current concepts and past controversies | Q38541717 | ||
| Efficacy of antiviral chemotherapy for retrovirus-infected cats: What does the current literature tell us? | Q38612672 | ||
| Focus on the therapeutic efficacy of 3BNC117 against HIV-1: In vitro studies, in vivo studies, clinical trials and challenges | Q38634979 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | macrophage | Q184204 |
| eradication of infectious diseases | Q1347969 | ||
| P304 | page(s) | 68-93 | |
| P577 | publication date | 2018-10-13 | |
| P1433 | published in | Journal of Neuroimmune Pharmacology | Q6295645 |
| P1476 | title | Current and Future Therapeutic Strategies for Lentiviral Eradication from Macrophage Reservoirs | |
| P478 | volume | 14 |
Search more.